Post Reply
61-80 of 12336
山 重 水 复 疑 无 路 ， 柳 暗 花 明 又 一 村
look like you should have exited .... so you should be safe
managed to pick up some. that is the obvious but many are unaware what they are doing fully .... so just watch
will collect as people start to throw down .... probably someone is accumulating 😂 😂 😂 😂 😂 😂 😂
will collect as people start to throw down .... probably someone is accumulating 😂 😂 😂 😂 😂 😂 😂
haha ... you always amazes me ...
the coy is making so many changes and restructuring .... reduce waste and all
i took profit long ago .... i am glad you are helping to bring the price down ... I must say a Big Thank You.
just wait for the work to be done and you will see it soar to the sky 飞 上 枝 头 变 凤 凰
名 字 取 得 好 ， 九 天 九 天
the coy is making so many changes and restructuring .... reduce waste and all
i took profit long ago .... i am glad you are helping to bring the price down ... I must say a Big Thank You.
just wait for the work to be done and you will see it soar to the sky 飞 上 枝 头 变 凤 凰
名 字 取 得 好 ， 九 天 九 天
With the new lowered forecast by china of 4.5 percent of GDP growth, I think this company can close shop soon
Must say something auspicuous in the year of the Horse to spread positivity:
九 天 九 地 齐 贺 ， 鸿 运 满 堂
九 天 九 地 齐 贺 ， 鸿 运 满 堂
Tob231 ( Date: 04-Mar-2026 19:06) Posted:
|
JurongW, 你 太 厉 害 了 . 好 一 个 " 九 天 九 地 " ,
九 天 九 地 - 该 成 语 原 指 天 有 九 重 、 地 有 九 层 ， 引 申 为 绝 佳 的 防 御 与 进 攻 态 势 ， 常 用 于 形 容 空 间 广 大 、 地 位 差 距 巨 大 ， 属 于 描 述 极 端 情 况 的 成 语
九 天 就 是 恰 恰 如 此 , 不 是 未 到 ， 而 是 时 间 没 到 .... 你 要 忍 耐 .
九 天 九 地 - 该 成 语 原 指 天 有 九 重 、 地 有 九 层 ， 引 申 为 绝 佳 的 防 御 与 进 攻 态 势 ， 常 用 于 形 容 空 间 广 大 、 地 位 差 距 巨 大 ， 属 于 描 述 极 端 情 况 的 成 语
九 天 就 是 恰 恰 如 此 , 不 是 未 到 ， 而 是 时 间 没 到 .... 你 要 忍 耐 .
Tob231 ( Date: 04-Mar-2026 10:16) Posted:
|
九 天 - meaning nine heavens, the highest skies
As share price couldn' t live up to its name, might as well rename as 九 地 - meaning nine earths, the deepest grounds.
As share price couldn' t live up to its name, might as well rename as 九 地 - meaning nine earths, the deepest grounds.
Back where it belongs...in the gutters
there is sign of operational recovery and business activity has resumed ...
for now tiam tiam
for now tiam tiam
they have changed the structure and managed to lower the cost ... next, to raise the revenue
like i said, " holding a small remnant which i should have sold awhile ago" hmmm maybe i should add-on 0.023/4
like i said, " holding a small remnant which i should have sold awhile ago" hmmm maybe i should add-on 0.023/4
Tob231 ( Date: 09-Dec-2025 16:35) Posted:
|
All time buy and keep
Hold tight tight with stockist
Alot trader stuck
Waiting china BB
Taiwan BB
Hold tight tight with stockist
Alot trader stuck
Waiting china BB
Taiwan BB
All time high stock market vs all time low share price says it all lol
祝 你 马 年 旺 旺 ， 万 事 如 意
马 年 兴 旺
马 到 成 功 ， 运 气 旺 旺
龙 马 精 神 ， 旺 旺 旺 ！
马 年 兴 旺
马 到 成 功 ， 运 气 旺 旺
龙 马 精 神 ， 旺 旺 旺 ！
UPDATED REPORT: Jiutian Chemical Group (SGX: C8R)
As of February 2026
Executive Summary
Jiutian Chemical Group remains in severe financial distress with signs of marginal operational improvement in 2025, though profitability remains elusive. The stock has declined to S$0.024-0.025 (February 2026), near historical lows. While 1H 2025 showed revenue growth of 74%, the company continues to burn cash with persistent net losses.
Current Stock Data (February 2026)
|
Metric |
Current Value |
|---|---|
|
Current Price |
S$0.024 - S$0.025 |
|
52-Week Range |
S$0.019 - S$0.042 |
|
Market Cap |
~S$46-48 million |
|
Price/Book |
0.43x - 0.60x |
|
Beta |
1.35 (increased volatility) |
|
Avg Volume |
~3.3 million shares |
|
Cash per Share |
~S$0.17 |
Updated Financial Performance (2024-2025)
FY 2024 Full Year (Audited)
-
Revenue: S$50.6M (down ~91.5% from S$598.6M in 2023) -
Net Loss: S$147.9M (continued deterioration) -
Profit Margin: -292.47% -
Cash Position: S$515.9M (significant war chest) -
Debt/Equity: 46.82%
1H 2025 Results (June 30, 2025) &mdash Signs of Stabilization
-
Revenue: CN¥ 83.1M (~S$15.5M) &mdash up 74% YoY from CN¥ 47.5M in 1H 2024 -
Net Loss: CN¥ 64.7M (~S$12.1M) &mdash improved 23% from CN¥ 84.0M loss in 1H 2024 -
Loss per Share: CN¥ 0.033 -
Gross Loss: CN¥ 48.9M (improved from CN¥ 51.1M)
Key Drivers:
-
Trial production of new methylamine plant -
Resumption of chemical product sales in Q2 2025 -
Cost-cutting measures and liquidation of loss-making subsidiary -
Administrative expenses reduced
Q3 2025 Results (September 30, 2025)
-
Revenue: RMB 2.8M &mdash up 217% YoY from RMB 0.89M in Q3 2024 -
Shows continued operational momentum despite small absolute numbers
Financial Trajectory Analysis
|
Period |
Revenue (S$M) |
Net Income (S$M) |
Trend |
|---|---|---|---|
|
FY 2022 |
2,435 |
+490 |
Peak profitability |
|
FY 2023 |
599 |
-345 |
Sharp decline |
|
FY 2024 |
51 |
-148 |
Collapse |
|
1H 2024 |
47 |
-84 |
Continuing losses |
|
1H 2025 |
86 |
-128 |
Revenue recovery, still loss-making |
|
TTM (Jun 2025) |
86 |
-128 |
Slight improvement |
Critical Observations:
-
Revenue appears to have bottomed in 2024 and is recovering in 2025 -
However, gross margins remain deeply negative &mdash the company is selling products below production cost -
Net asset value per share dropped 10.5% to CN¥ 27.82 (1H 2025) -
Cash burn continues despite cost-cutting
Strategic Developments (2025)
Major Corporate Actions:
-
Proposed Diversification (Ongoing since 2024)-
Third extension of long-stop date (June 2025) -
Attempting to pivot away from pure DMF dependence -
Termination of framework agreements announced (December 2025)
-
-
Strategic Restructuring of Controlling Shareholders (September 2025)-
Potential change in ownership structure -
Could lead to new management or strategic direction
-
-
Arbitration Proceedings (July 2025)-
Received notice of arbitration &mdash legal risks remain
-
-
Board Changes-
New independent directors appointed (2024-2025) -
Company secretary changed (March 2025)
-
Industry Context Update (2025-2026)
The global DMF market continues to grow:
-
Market Size: USD 2.27B (2025) &rarr projected USD 2.71B (2030) -
CAGR: 3.8-4.1% -
Key Growth Drivers:-
Pharmaceutical peptide synthesis -
Lithium-ion battery manufacturing -
Electronics/OLED films -
Polyurethane production
-
Competitive Landscape:
-
Chinese overcapacity continues to pressure pricing -
Environmental regulations tightening in China -
Major players: Shandong Hualu Hengsheng, Luxi Chemical, BASF, Eastman Chemical
Updated Entry Price Analysis
Given the 2025 data showing revenue recovery but continued losses, here' s my revised entry framework:
TIER 1: Deep Value/Contrarian Entry &mdash S$0.018-0.022
-
Rationale: At S$0.02, market cap (~S$40M) is significantly below cash value (S$515M) -
Risk: High &mdash company could burn through remaining cash in 2-3 years at current burn rate -
Reward: 3-5x if operations turn profitable -
Stop Loss: S$0.015 (below 52-week low)
TIER 2: Speculative Recovery Play &mdash S$0.023-0.028
-
Rationale: Current trading range wait for Q4 2025/FY 2025 results to confirm trend -
Catalysts Needed:-
Positive gross margins (currently negative) -
Quarterly revenue > S$50M -
Announcement of successful diversification
-
-
Position Size: < 2% of portfolio
TIER 3: Confirmation Entry &mdash Above S$0.035
-
Rationale: Would indicate market confidence in turnaround -
Requirements:-
Two consecutive quarters of positive EBITDA -
Gross margin > 10% -
Clear path to profitability
-
Key Risks & Red Flags (Updated)
|
Risk Factor |
Severity |
Update |
|---|---|---|
|
Negative Gross Margins |
🔴 Critical |
Still losing money on every sale |
|
Cash Burn |
🔴 High |
S$515M cash provides ~3-4 years runway |
|
Arbitration |
🟡 Medium |
Legal overhang from July 2025 |
|
Diversification Failure |
🔴 High |
Third extension suggests difficulty |
|
Shareholder Restructuring |
🟡 Uncertain |
Could be positive or negative |
|
Delisting Risk |
🟡 Medium |
If performance doesn' t improve |
Investment Thesis Update
Bull Case (20% probability)
-
Revenue recovery continues into 2026 -
New methylamine plant achieves commercial viability -
Diversification strategy succeeds -
Takeover target at 0.5-1.0x book value -
Target: S$0.08-0.12 (3-5x return)
Base Case (50% probability)
-
Continued stagnation with occasional revenue spikes -
Break-even achieved by 2027 -
Stock trades range-bound S$0.02-0.04 -
Return: 0-50% over 2 years
Bear Case (30% probability)
-
Cash burn accelerates -
Diversification fails -
Equity raise/dilution or liquidation -
Downside: -50% to -100%
Recommendation
HOLD/AVOID for conservative investors. SPECULATIVE BUY only for high-risk tolerance investors with the following conditions:
-
Entry: Scale in between S$0.020-0.024 -
Position Size: Maximum 1-2% of portfolio -
Stop Loss: S$0.018 (25% downside protection) -
Time Horizon: 2-3 years minimum -
Catalyst Watch:-
FY 2025 results (March 2026) -
Q1 2026 quarterly disclosure (April 2026) -
Resolution of diversification strategy
-
Critical: The company is showing operational improvement but is not yet investable from a fundamental perspective. The 74% revenue growth in 1H 2025 is encouraging, but until gross margins turn positive, this remains a speculative punt on asset value rather than a business investment.
Current Status: The stock is cheaper than 2024 (S$0.024 vs S$0.028), but the risk profile remains extreme. Wait for Q4 2025 results before committing significant capital.
wait 九 九
我 来 也 , 该 来 的 就 会 来
我 倒 要 看 九 天 是 什 么 来 头
没 事 的
我 倒 要 看 九 天 是 什 么 来 头
没 事 的
來 了
是 的 . 该 来 的 就 会 来
龙 的 传 人
龙 的 传 人